Current Report Filing (8-k)
June 20 2018 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 14, 2018
Date of Report (Date of earliest event reported)
AEVI GENOMIC MEDICINE, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices,
zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
On June 14, 2018, Aevi Genomic Medicine,
Inc.’s (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The final
results for each of the matters submitted to a vote of stockholders at the Annual Meeting are as follows:
Proposal 1:
The election of seven
directors to serve on the Board of Directors until the next annual meeting of stockholders and until their respective successors
are duly elected and qualified.
Nominee
|
For
|
Against
|
Abstained
|
Broker Non-Votes
|
Sol J. Barer
|
32,488,467
|
270,775
|
140,886
|
14,518,011
|
Eugene A. Bauer
|
32,526,536
|
201,745
|
171,847
|
14,518,011
|
Alastair Clemow
|
31,406,576
|
1,320,766
|
172,786
|
14,518,011
|
Michael F. Cola
|
32,542,088
|
172,333
|
185,707
|
14,518,011
|
Barbara G. Duncan
|
32,047,100
|
709,708
|
143,320
|
14,518,011
|
Matthew D. Bayley
|
32,507,900
|
165,346
|
226,882
|
14,518,011
|
Joseph J. Grano, Jr.
|
31,417,929
|
1,338,613
|
143,586
|
14,518,011
|
Proposal 2:
The amendment
to the Company’s Stock Incentive Plan, to increase the number of shares of common stock available under the plan from 9,178,571
shares to 13,178,571 shares.
For
|
Against
|
Abstained
|
Broker Non-Votes
|
29,270,497
|
3,575,696
|
53,935
|
14,518,011
|
Proposal 3:
The ratification
of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal
year ending December 31, 2018.
For
|
Against
|
Abstained
|
46,528,621
|
84,549
|
804,969
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AEVI GENOMIC MEDICINE, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Brian D. Piper
|
|
|
|
Name: Brian D. Piper
|
|
|
|
Title: Chief Financial Officer and
Corporate Secretary
|
|
Date: June 20, 2018
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Apr 2023 to Apr 2024